Method for preventing or treating cisplatin-induced nephrotoxicity

Abstract

Provided is a method for preventing or treating cisplatin induced nephrotoxicity, which comprises administering a patient who is receiving cisplatin a therapeutically effective amount of an aldosterone blocker such as eplerenone or spironolactone.

1 . A method for preventing or treating a condition or disease caused by Cisplatin-induced nephrotoxicity, which comprises administering a therapeutically effective amount of an aldosterone blocker to a patient who is receiving Cisplatin. 
   
   
       2 . The method of  claim 1 , wherein the patient is a human being treated for cancer. 
   
   
       3 . The method of  claim 1 , wherein the aldosterone blocker and Cisplatin are co-administered to the patient in different formulations. 
   
   
       4 . The method of  claim 1 , wherein aldosterone blocker is Spironolactone or Eplerenone. 
   
   
       5 . The method of  claim 1 , wherein the patient is receiving one or more anti-cancer agents other than Cisplatin. 
   
   
       6 . The method of  claim 1 , wherein the patient is receiving radiation. 
   
   
       7 . The method of  claim 1 , wherein the condition caused by Cisplatin-induced nephrotoxicity is acute renal failure. 
   
   
       8 . A method for preventing accumulation of Cisplatin in the kidney, which comprises administering a therapeutically effective amount of an aldosterone blocker to a patient who is receiving Cisplatin. 
   
   
       9 . A method for treating caner, which comprises administering a therapeutically effective amount of Cisplatin and an aldosterone blocker to a patient in need thereof.